Understanding the Class Action Lawsuit Opportunity for Investors
In a significant development, Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit on behalf of investors of Agenus Inc. facing substantial losses. This lawsuit presents an opportunity for affected investors to take action against the company and its executives.
What Is the Class Definition?
The lawsuit aims to recover damages for alleged violations of federal securities laws. It includes all individuals and entities that purchased or acquired Agenus securities during the Class Period, which spans from January 23, 2023, to July 17, 2024. Investors who believe they have suffered losses during this timeframe are encouraged to participate in the lawsuit.
Details of the Case
Throughout the class period, the Complaint alleges that the company and its officers made misleading statements regarding the effectiveness of their therapies. Specifically, the claims assert that the combination therapy of botensilimab and balstilimab was not as effective as communicated to investors. Concerns were raised about the accuracy of clinical trial results and the true commercial prospects of these therapies.
Next Steps for Investors
A class action lawsuit has already been initiated. Investors looking to review the Complaint or who have questions regarding their eligibility should reach out to Bronstein, Gewirtz & Grossman, LLC. Notably, there is a deadline for investors to request the Court to appoint them as lead plaintiff, which is crucial for those seeking to lead the case.
No Financial Obligation Required
Importantly, Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis. This means that investors can participate in this class action without upfront costs. The firm will seek reimbursement for expenses and legal fees only if the lawsuit is successful, making it a low-risk option for affected investors.
About Bronstein, Gewirtz & Grossman, LLC
This law firm is renowned for representing investors in securities fraud cases and shareholder derivative lawsuits. They have a strong track record, recovering substantial amounts for their clients nationwide. Their dedicated team is prepared to assist investors in navigating this legal process.
Contact Information
Investors interested in learning more or who have further inquiries can contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
Phone: 332-239-2660
Email: info@bgandg.com
Frequently Asked Questions
What is a class action lawsuit?
A class action lawsuit allows a group of people with similar claims against a defendant to file a single lawsuit collectively, which can streamline the legal process.
Who can join the class action against Agenus Inc.?
Any investor who purchased Agenus securities during the specified class period may join the class action to seek restitution for their losses.
What are the claims made in the lawsuit?
The lawsuit claims that Agenus and its officers made false statements about the effectiveness and commercial prospects of their therapies, leading to investor losses.
Is there a cost to join the lawsuit?
No, joining the class action requires no upfront payment. The law firm operates on a contingency basis.
How can I find out more about the lawsuit?
Investors can visit the law firm's website or contact them directly for more information about participation in the class action lawsuit.
